ParkerVision updates resale of up to 13.3M shares

ParkerVision receives no proceeds from stockholder resales, while cash exercise of the warrants could provide up to $2,833,756 in gross proceeds.

Rhea-AI Filing Summary

ParkerVision, Inc. updates its resale prospectus, which permits selling stockholders to resell up to 13,342,953 shares of common stock. The registered amount comprises 7,962,722 shares issued under securities purchase agreements, 3,230,942 shares issued under a March 29, 2021 agreement, 1,619,289 shares underlying warrants issued under that agreement, and 530,000 shares issued as payment for services.

ParkerVision will receive no proceeds from stockholder resales. If the warrants are exercised for cash, ParkerVision may receive up to $2,833,756 in gross proceeds and expects to use any proceeds received for general working capital, including payment of litigation expenses.

Filing Explained

The patent case returns to district court, while this prospectus-maintenance filing issues no new shares.

The October 1, 2026 Form 8-K reports an order in ParkerVision’s expedited patent appeal; a same-day news headline identifies it as a remand to district court, returning the case there for its next stage.

The company says this 424B3 updates existing registration statements to maintain effectiveness and does not involve a new securities issuance, so this filing issues no new shares.

Sources and calculations

• ParkerVision Prospectus Supplement No. 63 and attached Form 8-K (2026-10-01)
• Federal Circuit remand headline (2026-10-01)

Key Figures

Registered resale shares: Up to 13,342,953 shares Shares issued under securities purchase agreements: 7,962,722 shares Shares issued under the March 29, 2021 agreement: 3,230,942 shares +3 more

6 metrics

Registered resale shares Up to 13,342,953 shares Common stock permitted for resale by selling stockholders

Shares issued under securities purchase agreements 7,962,722 shares Included in the registered resale amount

Shares issued under the March 29, 2021 agreement 3,230,942 shares Included in the registered resale amount

Shares underlying Warrants 1,619,289 shares Included in the registered resale amount

Shares issued for services 530,000 shares Included in the registered resale amount

Potential gross proceeds from cash warrant exercises Up to $2,833,756 ParkerVision receives proceeds only to the extent Warrants are exercised for cash

Key Terms

selling stockholders, securities purchase agreements, Warrants, gross proceeds

4 terms

selling stockholders regulatory

"resale by the selling stockholders listed in the Prospectus"

Selling stockholders are existing owners of a company's shares who are offering some or all of their holdings for sale, often as part of a public offering or secondary transaction. For investors this matters because such sales increase the number of shares available to buy, can signal how confident current owners are about future prospects, and may put short-term pressure on the stock price similar to more tickets being released for a popular event.

securities purchase agreements financial

"shares of Common Stock issued pursuant to securities purchase agreements"

A securities purchase agreement is a legal contract that spells out the terms when a company sells stocks, bonds, or other investment instruments to buyers. It lays out price, how many securities change hands, any promises or protections for each side, and when the sale is completed—like a detailed sales contract for investments. Investors care because it determines ownership stakes, potential dilution, rights attached to the securities, and conditions that affect the company’s future value.

Warrants financial

"shares of Common Stock underlying warrants (“Warrants”)"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

gross proceeds financial

"$2,833,756 in gross proceeds"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

Offering Details

secondary · Up to 13,342,953 shares

Offering

Offering Type secondary

Securities Offered Common stock

Offering Amount Up to 13,342,953 shares

Use of Proceeds ParkerVision receives no proceeds from stockholder resales. If Warrants are exercised for cash, it expects to use any proceeds received for general working capital, including payment of litigation expenses.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PRKR shares are registered for resale?

Selling stockholders may resell up to 13,342,953 shares of common stock under the prospectus.

Will ParkerVision receive proceeds from PRKR stockholder resales or warrant exercises?

ParkerVision receives no proceeds from stockholder resales. If the warrants are exercised for cash, it may receive up to $2,833,756 in gross proceeds, which it expects to use for general working capital, including payment of litigation expenses.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 06:03 PM Accepted by SEC EDGAR 10/01/2026 - 04:03 PM Learn about SEC filing dates

Filed pursuant to Rule 424(b)(3)

Registration No. 333-255217

PROSPECTUS SUPPLEMENT No. 63

(to Prospectus dated April 26, 2021)

PARKERVISION, INC.

13,342,953 Shares of Common Stock

This Prospectus Supplement relates to the prospectus dated April 26, 2021, as amended and supplemented from time to time (the “Prospectus”), which permits the resale by the selling stockholders listed in the Prospectus of up to 13,342,953 shares of our common stock, par value $0.01 per share (“Common Stock”) consisting of (i) an aggregate of 7,962,722 shares of Common Stock issued pursuant to securities purchase agreements dated October 5, 2020, November 17, 2020, December 11, 2020, December 21, 2020 and January 5, 2021, (ii) an aggregate of 3,230,942 shares of Common Stock and 1,619,289 shares of Common Stock underlying warrants (“Warrants”) issued pursuant to securities purchase agreements dated March 29, 2021, (iii) 530,000 shares of Common Stock issued as payment for services.

We will not receive proceeds from the sale of the shares of Common Stock by the selling stockholders. To the extent the Warrants are exercised for cash, we will receive up to an aggregate of $2,833,756 in gross proceeds.  We expect to use the proceeds received from the exercise of the Warrants, if any, for general working capital purposes, including payment of litigation expenses.

This Prospectus Supplement is being filed to update and supplement the information previously included in the Prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on October 1, 2026.  Accordingly, we have attached the 8-K to this prospectus supplement.  You should read this prospectus supplement together with the prospectus, which is to be delivered with this prospectus supplement.

Any statement contained in the Prospectus shall be deemed to be modified or superseded to the extent that information in this Prospectus Supplement modifies or supersedes such statement.  Any statement that is modified or superseded shall not be deemed to constitute a part of the Prospectus except as modified or superseded by this Prospectus Supplement. 

This Prospectus Supplement should be read in conjunction with, and may not be delivered or utilized without, the Prospectus.

Our Common Stock is listed on the OTCQB Venture Capital Market under the ticker symbol “PRKR.”

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 6 of the Prospectus for a discussion of information that should be considered in connection with an investment in our securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or determined whether this Prospectus or Prospectus Supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this Prospectus Supplement is October 1, 2026.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 1, 2026

PARKERVISION, INC.

(Exact Name of Registrant as Specified in Charter)

Florida	000-22904	59-2971472
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4446-1A Hendricks Avenue Suite 354, Jacksonville, Florida	32207
(Address of Principal Executive Offices)	(Zip Code)

(904) 732-6100

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
None

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter.

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Item 8.01 Other Events

On October 1, 2026,  ParkerVision, Inc. (the “Company”) issued a press release announcing that the Court of Appeals for the Federal Circuit issued its order in the expedited appeal of the Company's patent infringement case against Qualcomm.  A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Current Report on Form 8-K, including Exhibit 99.1 hereto, has been “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section. The information in this Current Report shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

The Company will file prospectus supplements on Form 424B3 to update previously filed S-1 registration statements to maintain their effectiveness.  These Form 424B3 filings typically follow the filing of the Company's periodic reports with the SEC, including Forms 8-K, and do not involve the issuance of any new securities by the Company.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit	Description
99.1	Press Release
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 1, 2026

PARKERVISION, INC.

By /s/ Cynthia French

Cynthia French

Chief Financial Officer